OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bhat on ELEVATE-TN Results in Treatment-Naïve CLL

October 21st 2020

Seema A. Bhat, MD, discusses the results of the phase 3 ELEVATE-TN trial in patients with treatment-naïve CLL.

Dr. Lwin on the Design of the LEAP-005 Trial in Pretreated Advanced Solid Tumors

October 20th 2020

Zarnie Lwin, MBBS, FRACP, discusses the design of the phase 2 LEAP-005 trial in previously treated patients with advanced solid tumors.

Dr. Skarbnik on Frontline Treatment Considerations in CLL

October 20th 2020

Alan P. Z. Skarbnik, MD, discusses frontline treatment considerations in chronic lymphocytic leukemia.

Dr. Abraham on the Clinical Utility of Pexidartinib in TGCT

October 20th 2020

John A. Abraham, MD, FACS, discusses the clinical utility of pexidartinib in tenosynovial giant cell tumor.

Dr. Hill on the FDA Approval of Brexucabtagene Autoleucel in Relapsed/Refractory MCL

October 20th 2020

Brian T. Hill, MD, PhD, discusses the FDA approval of brexucabtagene autoleucel for patients with relapsed/refractory mantle cell lymphoma.

Dr. Ocean on Determining Optimal Frontline Treatments for Metastatic Pancreatic Cancer

October 20th 2020

Allyson Ocean, MD, discusses determining the optimal frontline treatment of patients with metastatic pancreatic cancer.

Dr. Galligan on Transplant Eligibility and Subsequent Treatments in Multiple Myeloma

October 20th 2020

Derek C. Galligan, MD, discusses transplant eligibility in determining subsequent treatment for patients with multiple myeloma.

Dr. Azad on the Design of the ARCHES Trial in mHSPC

October 20th 2020

Arun Azad, PhD, discusses the design of the phase 3ARCHES trial in metastatic hormone-sensitive prostate cancer.

Dr. Kantoff on the Rationale to Evaluate VERU-111 in mCRPC

October 20th 2020

Philip W. Kantoff, MD, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer.

Dr. Hussain on the Need for Effective Treatment in Nonmetastatic CRPC

October 20th 2020

Maha Hussain, MD, FACP, FASCO, discusses the need for treatment that elicits an overall survival benefit in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Jackson on VEGF Versus PARP Inhibitors in Recurrent Ovarian Cancer

October 19th 2020

Amanda L. Jackson, MD, discusses choosing between VEGF inhibitors and PARP inhibitors in the treatment of patients with recurrent platinum-sensitive ovarian cancer.

Dr. Shore on the Design of the HERO Trial With Relugolix in Advanced Prostate Cancer

October 19th 2020

Neal D. Shore, MD, FACS, discusses the design of the phase 3 HERO trial in patients with advanced prostate cancer.

Dr. Bhat on the FDA Approval of Acalabrutinib in CLL

October 19th 2020

Seema A. Bhat, MD, discusses the approval of acalabrutinib in chronic lymphocytic leukemia based on data from the phase 3 ELEVATE-TN trial.

Dr. Masarova on Future Research in MPNs

October 19th 2020

Lucia Masarova, MD, discusses future research efforts in myeloproliferative neoplasms.

Dr. Paplomata on the Role of Tucatinib/Trastuzumab/Capecitabine in HER2+ Metastatic Breast Cancer

October 19th 2020

Elisavet Paplomata, MD, discusses the role of tucatinib in combination with trastuzumab and capecitabine in HER2-positive metastatic breast cancer.

Dr. Azad on the Importance of Germline Testing in CRC

October 19th 2020

Nilofer Saba Azad, MD, discusses the significance of germline testing in colorectal cancer.

Dr. Nagle on Sequencing Challenges in Multiple Myeloma

October 19th 2020

Sarah Nagle, MD, discusses sequencing challenges in multiple myeloma.

Dr. Maki on the Utility of Tazemetostat in Epithelioid Sarcoma

October 19th 2020

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the utility of tazemetostat in epithelioid sarcoma.

Dr. Brar on the Need to Identify Biomarkers in HCC

October 19th 2020

Gagandeep Brar, MD, discusses the need to identify biomarkers in hepatocellular carcinoma.

Dr. Mesa on the Rationale for the Earlier Use of Ruxolitinib in Myelofibrosis

October 16th 2020

Ruben A. Mesa, MD, discusses the rationale for the earlier use of ruxolitinib in myelofibrosis.